Related references
Note: Only part of the references are listed.Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations
Don Husereau et al.
VALUE IN HEALTH (2022)
A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing
Sarah Glewis et al.
BRITISH JOURNAL OF CANCER (2022)
Teletrials: implementation of a new paradigm for clinical trials
Ian M. Collins et al.
MEDICAL JOURNAL OF AUSTRALIA (2020)
Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype
David Paez et al.
BRITISH JOURNAL OF CANCER (2019)
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy
Linda M. Henricks et al.
EUROPEAN JOURNAL OF CANCER (2019)
Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis
Linda M. Henricks et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
Femke M. de Man et al.
CLINICAL PHARMACOKINETICS (2018)
Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers
Carin A. T. C. Lunenburg et al.
EUROPEAN JOURNAL OF CANCER (2018)
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
Linda M. Henricks et al.
LANCET ONCOLOGY (2018)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
Ursula Amstutz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
Maarten J. Deenen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
Didier Meulendijks et al.
LANCET ONCOLOGY (2015)